An Indian Multicentric, Open Label, Prospective Phase IV Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-Life Clinical Practice

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS3724
• Study ID:
  40367
• Official title and acronym:
  An Indian Multicentric, Open Label, Prospective Phase IV Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-Life Clinical Practice
• DARWIN EU® study:
  No
• Study countries:
  India
• Study description:
  This is a Phase IV, single-arm, open-label, prospective, interventional, multicenter study of bevacizumab (Avastin) in real-life clinical setting. This study plans to enroll 100 subjects at approximately 20 sites across India.
• Study status:
  Finalised

Research institutions and networks

Institutions

F. Hoffmann-La Roche

Multiple centres: 20 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned:01/11/2012

Actual:01/11/2012

Study start date

Planned:28/11/2018

Actual:05/12/2018

Data analysis start date

Actual:18/06/2025

Date of final study report

Planned:31/10/2025

Actual:06/02/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Hoffmann-La Roche (Roche Products (India) Pvt, Ltd)

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only

Other study registration identification numbers and links

ML28446